Erster Patient der LION-1-Studie erhält Immunzelltherapie gegen neues Zielmolekül
Welcome to the Hudecek Lab – The home of CAR T
Our research
We are developing novel personalized immune-based cancer treatments that involve reprogramming of the patient’s own immune system cells which are then used to target and destroy cancer cells.
Our approach
We are equipping T cells (white blood cells) with a biosensor (chimeric antigen receptor, CAR) to help them detect and eliminate cancer cells.
Latest publications

Jaeckel E, Friedman SL, Hudecek M, Protzer U.
Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases.
J Hepatol. 2025 Jun 20:S0168-8278(25)02274-3
Go to publication
De Angelis B, D'Amore ML, Lecot P, Neininger K, Lorrain M, Gambotti L, Dreuillet C, Courcault E, Chatterjee S, Delgado J, Galy A, Franz P, Rodriguez-Madoz JR, Cabrerizo Y, Richter A, Girvalaki C, Noviello M, Tassi E, Sanges C, Luu M, Hudecek M, Kremer A, Locatelli F, Negre H, Quintarelli C.
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring.
Front Immunol. 2025 Apr 24;16:1567582
Go to publication
Hinckley-Boned A, Barbero-Jiménez C, Tristán-Manzano M, Maldonado-Perez N, Hudecek M, Justicia-Lirio P, Martin F.
Tailoring CAR surface density and dynamics to improve CAR-T cell therapy.
J Immunother Cancer. 2025 Apr 29;13(4):e010702
Go to publication
Wegner VD, Feile A, Alb M, Hudecek M, Hewitt P, Mosig AS.
Short-Chain Fatty Acids Modulate Anti-ROR1 CAR T-Cell Function and Exhaustion in an Intestinal Adenocarcinoma-on-Chip Model.
Adv Healthc Mater. 2025 May;14(13):e2405003
Go to publication
Peter J, Toppeta F, Trubert A, Danhof S, Hudecek M, Däullary T.
Multi-Targeting CAR-T Cell Strategies to Overcome Immune Evasion in Lymphoid and Myeloid Malignancies.
Oncol Res Treat. 2025;48(5):265-279
Go to publication
Dragon AC, Bonifacius A, Lienenklaus S, Verboom M, Gerhards JP, Ius F, Hinze C, Hudecek M, Figueiredo C, Blasczyk R, Eiz-Vesper B. Depletion of alloreactive B cells by drug-resistant chimeric alloantigen receptor T cells to prevent transplant rejection.
Mol Ther. 2025 Mar 5;33(3):1031-1047
Go to publication
Fleischer A, Kurth S, Duell J, Topp M, Strunz PP, Mersi J, Rasche L, Sanges C, Hudecek M, Einsele H, Maatouk I.
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies.
J Immunother Cancer. 2024 Dec 22;12(12):e009174
Go to publication
Jacobs JJL, Beekers I, Verkouter I, Richards LB, Vegelien A, Bloemsma LD, Bongaerts VAMC, Cloos J, Erkens F, Gradowska P, Hort S, Hudecek M, Juan M, Maitland-van der Zee AH, Navarro-Velázquez S, Ngai LL, Rafiq QA, Sanges C, Tettero J, van Os HJA, Vos RC, de Wit Y, van Dijk S.
A data management system for precision medicine.
PLOS Digit Health. 2025 Jan 9;4(1):e0000464
Go to publication
Gehrke L, Gonçalves VDR, Andrae D, Rasko T, Ho P, Einsele H, Hudecek M, Friedel SR.
Current Non-Viral-Based Strategies to Manufacture CAR-T Cells.
Int J Mol Sci. 2024 Dec 21;25(24):13685
Go to publication
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, Maulana TI, van der Meer AD, Weener HJ, Clerbaux LA, Fogal B, Patel N, Adkins K, Lund E, Perkins E, Cooper C, van den Brulle J, Morgan H, Rubic-Schneider T, Ling H, DiPetrillo K, Moggs J, Köhl U, Hudecek M.
Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept.
J Immunotoxicol. 2024 Oct;21(sup1):S13-S28
Go to publication
Contact person
Univ.-Prof. Dr. med.
Michael Hudecek
Director and Research Group Leader Translational CAR-T Research Program